Data from Investigation of Established Genetic Risk Variants for Glioma in Prediagnostic Samples from a Population-Based Nested Case–Control Study

Abstract

<div>Abstract<p><b>Background:</b> Although glioma etiology is poorly understood in general, growing evidence indicates a genetic component. Four large genome-wide association studies (GWAS) have linked common genetic variants with an increased glioma risk. However, to date, these studies are based largely on a case–control design, where cases have been recruited at the time of or after diagnosis. They may therefore suffer from a degree of survival bias, introduced when rapidly fatal cases are not included.</p><p><b>Methods:</b> To confirm glioma risk variants in a prospective setting, we have analyzed 11 previously identified risk variants in a set of prediagnostic serum samples with 598 cases and 595 matched controls. Serum samples were acquired from The Janus Serum Bank, a Norwegian population-based biobank reserved for cancer research.</p><p><b>Results:</b> We confirmed the association with glioma risk for variants within five genomic regions: 8q24.21 (<i>CCDC26</i>), 9p21.3 (<i>CDKN2B-AS1</i>), 11q23.3 (<i>PHLDB1</i>), 17p13.1 (<i>TP53</i>), and 20q13.33 (<i>RTEL1</i>). However, previously identified risk variants within the 7p11.2 (<i>EGFR</i>) region were not confirmed by this study.</p><p><b>Conclusions:</b> Our results indicate that the risk variants that were confirmed by this study are truly associated with glioma risk and may, consequently, affect gliomagenesis. Though the lack of positive confirmation of EGFR risk variants may be attributable to relatively limited statistical power, it nevertheless raises the question whether they truly are risk variants or markers for glioma prognosis.</p><p><b>Impact:</b> Our findings indicate the need for further studies to clarify the role of glioma risk loci with respect to prolonged survival versus etiology. <i>Cancer Epidemiol Biomarkers Prev; 24(5); 810–6. ©2015 AACR</i>.</p></div>